Site Search

Two Phase 3 clinical trials of tezacaftor (VX-661) in combination with ivacaftor (Kalydeco®) showed positive results, Vertex Pharmaceuticals announced today.

Positive results from a study of ivacaftor (Kalydeco®) in children ages 1 to 2 were announced today.

Aim is to Provide Cystic Fibrosis Patients Enhanced Access to Medications and Expanded Pharmacy Services

Before you can walk a mile in a person with CF's shoes, you have to put on a nebulizer.

When your life is already jam-packed with nebulizing medications, why would you add one more?

Antibiotics fight infections caused by bacteria. They should not be used to treat infections caused by viruses (such as the flu) or types of fungi, which include yeasts and molds.

Update: On February 3, 2017, the Cystic Fibrosis Foundation divested its remaining ownership stake in CF Services Inc., a specialty pharmacy. The pharmacy is now fully owned by Walgreens.

The imagination can run wild thinking of all the possible scenarios that could happen after trying the new triple-combination modulator, Trikafta™. Managing expectations -- while allowing yourself to hope -- is how I choose to approach my wait for the new drug.